AVC-203 / AvenCell Therap - LARVOL DELTA

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program (PRNewswire) - "AvenCell Japan...announced it has been awarded a grant of up to $40 million from the Japan Agency for Medical Research and Development (AMED). This non-dilutive funding will support the worldwide development of AvenCell's AVC203 candidate - an IND-stage, dual-antigen (CD19 & CD20) allogeneic CAR-T therapy for applications in B-cell Lymphomas."

Financing • B Cell Lymphoma